The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response

Journal of Cellular Immunotherapy Pub Date : 2016-03-01 DOI:10.1016/j.jocit.2015.01.001

Milaid Granadillo , Alain B. Alfonso , Maribel G. Vallespi , Aileen Batte , Yordanka Soria , Enma Brown , Miladys Limonta , Yayrí C. Prieto , Laura Varas , Isis Torrens

{"title":"The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response","authors":"Milaid Granadillo , Alain B. Alfonso , Maribel G. Vallespi , Aileen Batte , Yordanka Soria , Enma Brown , Miladys Limonta , Yayrí C. Prieto , Laura Varas , Isis Torrens","doi":"10.1016/j.jocit.2015.01.001","DOIUrl":null,"url":null,"abstract":"<div><p>Aluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is common knowledge that these adjuvants predominantly induce humoral immunity, but some reports also describe their role combined with IL-12 in the induction of a Th1 immune response. In this study we want to investigate if alum could be an adjuvant to be used as a component of a therapeutic vaccine that require the generation of cell-mediated immunity. To demonstrate this concept we selected the human papillomavirus (HPV) 16-transformed mouse TC-1 cells as model and the fusion protein LALF<sub>32-51</sub>-E7 as antigen. Our results suggest that LALF<sub>32-51</sub>-E7 combined with aluminum hydroxide adjuvant promotes a Th1 immune response and consequently an anti-tumor response in the TC-1 tumor model. These results could have important application in future clinical trials in women with low grade squamous intraepithelial neoplasia.</p></div>","PeriodicalId":100761,"journal":{"name":"Journal of Cellular Immunotherapy","volume":"2 1","pages":"Pages 44-51"},"PeriodicalIF":0.0000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jocit.2015.01.001","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cellular Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352177515000035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Aluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is common knowledge that these adjuvants predominantly induce humoral immunity, but some reports also describe their role combined with IL-12 in the induction of a Th1 immune response. In this study we want to investigate if alum could be an adjuvant to be used as a component of a therapeutic vaccine that require the generation of cell-mediated immunity. To demonstrate this concept we selected the human papillomavirus (HPV) 16-transformed mouse TC-1 cells as model and the fusion protein LALF_32-51-E7 as antigen. Our results suggest that LALF_32-51-E7 combined with aluminum hydroxide adjuvant promotes a Th1 immune response and consequently an anti-tumor response in the TC-1 tumor model. These results could have important application in future clinical trials in women with low grade squamous intraepithelial neoplasia.

查看原文本刊更多论文

LALF32-51肽作为HPV治疗性疫苗的组成部分绕过铝介导的IL-12抑制并促进Th1反应

含铝佐剂(明矾)仍然是最广泛使用的佐剂。众所周知，这些佐剂主要诱导体液免疫，但一些报道也描述了它们与IL-12联合诱导Th1免疫应答的作用。在这项研究中，我们想要研究明矾是否可以作为一种佐剂，作为需要产生细胞介导免疫的治疗性疫苗的组成部分。为了证明这一概念，我们选择了人乳头瘤病毒(HPV) 16转化的小鼠TC-1细胞作为模型，融合蛋白LALF32-51-E7作为抗原。我们的研究结果表明LALF32-51-E7联合氢氧化铝佐剂可促进TC-1肿瘤模型的Th1免疫应答，从而产生抗肿瘤应答。这些结果可能在未来的低级别鳞状上皮内瘤变妇女的临床试验中具有重要的应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cellular Immunotherapy

自引率

0.00%

发文量